Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABRE: CAR-TA T Cells in Relapsed/Refractory Embryonal Tumors
NCT07172958Phase 1Recruiting
- Sponsor
- Children's National Research Institute
- Start
- Jan 2026
- Primary completion
- Dec 2041
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 3CAR in rhabdomyosarcoma (RMS), Ewing sarcoma, neuroblastoma and 1 more, sponsored by Children's National Research Institute. Primary endpoints: Safety of autologous CAR-TA T cells at 28 days, Manufacturing feasibility of autologous CAR-TA T cells at 28 days and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
3CAR
03
Conditions
rhabdomyosarcoma (RMS)Ewing sarcomaneuroblastomaWilms' tumor
Beyond the preview
Go deeper on NCT07172958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172958.